drug prices

Pharmalot By Ed Silverman

Pharmalittle: Trump to give speech today on drug pricing; FDA approves a novel, but pricey flu drug

Pharmalot By Ed Silverman

Here’s a hypothesis: Lower doses of some cancer pills could save a lot of money

Pharmalot By Ed Silverman

Mallinckrodt will be honored for research into a drug that causes sticker shock

Pharmalot By Ed Silverman

Minnesota becomes first state to sue major insulin makers over price-gouging

Pharmalot By Ed Silverman

Pharmalittle: Trump to require drug prices in ads; Europe cracks down on valsartan ingredients maker

Pharmalot By Ed Silverman

Pfizer pays $700,000 to settle charges over misleading copay coupons

Pharmalot By Ed Silverman

CVS sets a cost-effectiveness threshold for health plan coverage of most new drugs

Pharmalot By Ed Silverman

Trump plan to give private Medicare leverage over drug costs would boost PBMs and biosimilars

Pharmalot By Ed Silverman

Republican lawmakers want FTC to probe PBM mergers over drug pricing concerns

Pharmalot By Ed Silverman

A federal appeals court just slammed the door on Allergan’s deal with the Mohawk tribe

Pharmalot By Ed Silverman

U.K. health officials make a counteroffer to Vertex for its pricey cystic fibrosis drugs

Pharmalot By Ed Silverman

Under pressure from Trump, Pfizer agrees to roll back price hikes

Pharmalot By Ed Silverman

Can a federal drug discount program unlock savings for state prisons?

Pharmalot By Ed Silverman

Aetna pressures whistleblower who alleged CVS Caremark ripped off Medicare

Pharmalot By Ed Silverman

Pharmalittle: Amgen migraine drug costs less than expected; J&J halts development on Alzheimer’s drug

Pharmalot By Ed Silverman

AbbVie and J&J reverse course on a price hike in face of criticism

Pharmalot By Ed Silverman

Martin Shkreli was hardly an outlier when it came to jacking up prices on older drugs

Pharmalot By Ed Silverman

U.S. spending on prescription drugs rose less than 1 percent last year

Pharmalot By Ed Silverman

Pharmalittle: Amgen migraine drug show promise; DEA moves to tighten opioid rules

Pharmalot By Ed Silverman

Pharmalittle: Sanofi warns Canada over industry treatment; Pfizer got a big boost from the new tax law

Pharmalot By Ed Silverman

Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?

Pharmalot By Ed Silverman

NIH is urged to probe Aegerion patents for failing to disclose federal funding

Pharmalot By Ed Silverman

Pharmalittle: Pfizer paid its CEO how much? Glaxo says Brexit will not be cheap

Biotech By Adam Feuerstein and Damian Garde

Wall Street reacts to Regeneron, Sanofi cholesterol drug study results

Adam's Take By Adam Feuerstein

Martin Shkreli has been sentenced. The drug industry is trying to get away scot-free

Pharmalot By Ed Silverman

UnitedHealthcare will pass some rebates to consumers, but will this really lower drug prices?

Pharmalot By Ed Silverman

Advocates protest Novartis ‘bullying tactics’ over access to medicines in poor countries

Pharmalot By Ed Silverman

Despite ‘responsible’ price, Regeneron drug kept out of many patients’ hands by payers

Adam's Take By Adam Feuerstein

Acadia Pharma raised the price of its only drug twice but quarterly sales still disappoint